#EASD2021 #CKD

📍More #kidney outcomes from the DAPA-CKD trial

😃Dapagliflozin may

⤵️Acute Kidney Injury #AKI by 32%

⤵️albuminuria by... 29% compared with placebo

@EASDelearning @EASDnews

#EASD2021 #type2diabetes #PrecisionMedicine

TriMaster Trial

📍Study design paper👉https://tinyurl.com/TriMaster

📍Testing 2 hypothesis ... (after metformin+/-SU)
▶️1) BMI modifies TZD Rx response
▶️2) eGFR modifies SGLT2i Rx response

📍both compared to a DPP4i

📍3-way crossover study

#EASD2021

1/5

📍Results of the SUSTAIN-4 Trial presented by @SDelprato

📍52w open-label RCT, with a further extension

📍High CV risk ... #type2diabetes with either #tirzepatide (5-15mg) vs insulin glargine

📍study pop
63 yr
♀️ 37%
👱🏻‍♂️81.8%
Hx CV dis 86%

@EASDelearning

Professor Tina Vilsböll kicks off her session with the immense progress made with insulin since its discovery. #EASD2021 @TinaVilsb

Uptake of @mydiamate web-based self-help app for @type1diabetes fostering @mentalhealth in the Netherlands: steadily growing.@novonordisk @JDRFNL ... @DiabetesNL @ACBRD @PSAD_studygroup @amsterdamumc @DiabetesFonds